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94 The Journal of Thoracic and CardiovObjective: The contemporary risk of reoperative aortic valve replacement is ill-
defined. We therefore compared the recent early results of reoperative and primary
aortic valve replacement in our institution.
Methods: Between January 1993 and January 2001, a total of 162 patients under-
went reoperative aortic valve replacement with or without coronary artery bypass
grafting, and 2290 underwent primary aortic valve replacement with or without
coronary artery bypass grafting. The reoperative and primary groups were similar
with regard to gender (37% female in both), preoperative New York Heart Asso-
ciation functional class (2.8  1 vs 2.8  1), and ejection fraction (58%  15% vs
57%  15%). Patients undergoing reoperative aortic valve replacement were
younger than those undergoing primary aortic valve replacement (64  15 years vs
70 13 years, P .001). Previous prostheses were xenografts in 77 patients (48%),
homografts and autografts in 25 (15%), and mechanical prostheses in 60 (37%).
Mean time to reoperation was 9.7  6.8 years.
Results: Early mortality for reoperative aortic valve replacement (8/162, 5%) was
not statistically different from that for primary aortic valve replacement (71/2290,
3%, P .20). Endocarditis was more common in the reoperative group (22% vs 3%,
P  .001); when endocarditis was excluded from the analysis, early mortality was
3% in both groups. Multivariate predictors for early mortality were prosthetic valve
endocarditis (P .001, odds ratio 9.8), advanced preoperative functional class (P
.001, odds ratio 2.0), peripheral vascular disease (P  .008, odds ratio 2.0),
preserved left ventricular ejection fraction (P  .004, odds ratio 0.98), and male
gender (P  .009, odds ratio 0.49). After adjustment for these factors, there was no
difference in early mortality between the groups (P  .095).
Conclusion: The risk of reoperative aortic valve replacement is similar to that for
primary aortic valve replacement. These data support the expanded use of biopros-
thetic valves in younger patients.
ascular Surgery ● January 2005
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A
CDAortic valve replacement (AVR) is a fre-quently performed operation, with morethan 11,000 isolated procedures and almost12,000 combined with coronary artery by-pass grafting (CABG) reported to The So-ciety of Thoracic Surgeons (STS) database
in 2003 (http://www.ctsnet.org/file/STSNationalDatabase
Spring2004AdultCardiacExecutiveSummary.pdf). The op-
erative risk for isolated AVR according to the database has
fallen below 5%, and that for AVR with CABG below 5%,
at the most recent report. The contemporary risk of reop-
erative AVR, however, remains ill defined. This risk has
implications not only for the assessment of an individual
patient’s candidacy for reparative surgery but also for the
selection of prosthesis type—mechanical or biologic—
among younger patients and those with longer life expect-
ancies. We therefore examined our recent institutional ex-
perience with primary and reoperative AVR.
Patients and Methods
Patients
This study was reviewed and approved by the institutional review
board at the Mayo Clinic Rochester (Rochester, Minn). We se-
lected all patients undergoing primary or reoperative AVR at the
Mayo Clinic Rochester between January 1993 and January 2001
from a computer registry maintained prospectively and in accor-
dance with the STS guidelines for valve replacements.1 Suture
repair of perivalvular leaks was not considered reoperative AVR,
and patients undergoing AVR beyond a second procedure were
excluded. Patients undergoing concomitant mitral valve replace-
ments or repairs, aortic aneurysm repair, or composite aortic root
reconstruction were excluded on the grounds that the concomitant
procedures might add significantly to the observed operative risk,
making the results more difficult to interpret. Those undergoing
concomitant CABG were included because they constituted such a
large fraction of those undergoing reoperative AVR. Patients un-
dergoing tricuspid valve repair or replacement were not excluded,
because this additional procedure was judged unlikely to affect
operative risk significantly.
Patients undergoing either biologic or mechanical valve im-
plantation were included in both study groups because the type of
prosthesis was thought unlikely to affect early outcomes. Simi-
larly, those with both mechanical and biologic valves in place were
included in the reoperative group. A subset analysis compared
those with previous xenograft valves and mechanical prostheses.
According to these criteria, we selected 2290 patients who had
undergone primary AVR and 162 patients who had undergone
reoperative AVR.
Definitions
In accordance with STS guidelines,1 early operative mortality was
defined as death occurring within 30 days of operation or before
discharge from the hospital. Any abnormality resulting in stenosis
or regurgitation of the aortic valve that was not intrinsic to the
valve itself, such as pannus ingrowth, trauma, or surgical error,
was considered nonstructural dysfunction. In contrast, structural
The Journal of Thoracdysfunction was a change in valve function related to an intrinsic
abnormality causing stenosis or regurgitation, such as calcification
and leaflet tears. Any abnormality that caused malfunction of the
prosthetic valve that was deemed significant by the referring
physician and operating surgeon and that was not caused by
structural or nonstructural dysfunction was classified as clinical
dysfunction.
Patients with preoperative serum creatinine level of 2.0 mg/dL
or greater were considered to have renal insufficiency, whereas
postoperative renal insufficiency was defined by a creatinine level
of 2.0 mg/dL or greater or by a doubling of the preoperative
creatinine level. Requirement for dialysis was considered a com-
plication of surgery only if preoperative renal function was normal.
Patients who required intravenous nitrate therapy in the absence of
myocardial infarction were considered to have unstable angina.
Myocardial infarction was defined by the presence of two of the
following four criteria: (1) prolonged (20 minutes) typical chest
pain not relieved by rest or nitrates, (2) enzyme (creatine kinase
MB fraction, lactate dehydrogenase subtype 1, and troponin T)
level elevation, (3) any wall motion abnormality according to
echocardiography, ventriculography, or multiple gated acquisition
scanning, and (4) serial electrocardiogram with ST-T segment
changes or pathologic Q waves. Operations were considered emer-
gency if performed for cardiovascular instability necessitating a
procedure outside the normal operative schedule or if another
patient was displaced from a scheduled operation. Operations were
considered urgent if patients had symptoms necessitating hospi-
talization for evaluation and were in too unstable a condition for
discharge before an operative procedure. Neurologic symptoms
lasting less than 1 hour and neurologic deficits that resolved within
72 hours were considered transient neurologic deficits, whereas
stroke was a central neurologic deficit persisting longer than 72
hours. Gastrointestinal complications included gastrointestinal
bleeding necessitating transfusion or a change in anticoagulation
protocol, cholecystitis necessitating cholecystotomy drainage or
surgical intervention, pancreatitis according to elevated pancreatic
enzymes, or ischemic or gangrenous bowel requiring surgical
resection. Sternal wound infection was marked by antibiotic use,
incision and drainage, or a positive wound culture.
Statistical Analysis
Categorical factors were compared between groups with Fisher
exact tests. In groups with severity classifications, such as aortic
valve regurgitation, the P value was based on an absent versus
present response. Logistic regression models were used to con-
struct a multivariate model to predict operative mortality. A step-
wise selection technique was used to identify factors for the final
multivariate model.
Results
Primary Versus Secondary AVR
The mean age of patients in the reoperative group was
significantly less than that of those in the primary AVR
group (Table 1). Those undergoing reoperative AVR more
often had a history of previous stroke, despite less com-
monly having a diagnosis of peripheral vascular disease,
perhaps because of the previous valvular prostheses. Al-
ic and Cardiovascular Surgery ● Volume 129, Number 1 95
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CDthough the overall incidences of coronary artery disease
were similar in the two groups, angina pectoris was more
common at presentation among patients in the reoperative
AVR group. Some element of mitral regurgitation was
common in both groups, although it was noted to be severe
in degree in only a handful of patients. The surgeon’s reason
for leaving the mitral disease uncorrected is a matter of
conjecture, but presumably it was considered that the mitral
dysfunction would improve after successful AVR.
Patients undergoing primary AVR more commonly had a
mix of stenotic and regurgitant aortic valve disease, whereas
patients in the reoperative AVR group more often had
regurgitant aortic valve disease. The indications for reop-
erative AVR were structural dysfunction in 70 patients
(43.5%), nonstructural dysfunction in 24 (14.9%), perival-
TABLE 1. Demographic and clinical characteristics of pop
Age (y, mean)
Female (No.)
Renal insufficiency (No.)
Stroke (No.)
Any
Remote (2 wk)
Peripheral vascular disease (No.)
Diabetes mellitus (No.)
Chronic lung disease (No.)
New York Heart Association functional class (No.)
I
II
III
IV
Angina (No.)
Any
Unstable
Myocardial infarction (No.)
Hypertension (No.)
Bacterial endocarditis (No.)
Any
Active
Coronary artery disease
Any disease
Three-vessel disease (No.)
Ejection fraction 30% (No.)
Aortic valve disorder (No.)
Stenosis
Regurgitation
Mixed
Mitral valve disorder (No.)
Stenosis
Regurgitation
Severe regurgitationvular leak in 22 (13.7%), endocarditis in 21 (13.0%), clin-
96 The Journal of Thoracic and Cardiovascular Surgery ● Januaical dysfunction in 10 (6.2%), thrombosis in 4 (2.5%),
unspecified in 4 (2.5%), thromboembolism in 3 (1.9%),
progression of coronary artery disease in 2 (1.2%), and
progression of other valvular disease in 1 (0.6%). In the
primary group, surgery was indicated for calcific disease in
1342 patients (58.6%), bicuspid aortic valve in 732 (32.0%),
annular dilatation in 89 (3.9%), rheumatic disease in 39
(1.7%), endocarditis in 28 (1.2%), prolapse in 16 (0.7%),
unspecified or other in 27 (1.2%), hypertrophic obstructive
cardiomyopathy in 9 (0.4%), and collagen vascular disease
in 8 (0.3%).
Most operations in our series were elective in nature,
which probably reflects referral patterns to our institution
(Table 2). As one would anticipate, when only isolated
AVR was considered, bypass and crossclamp times were
ion
eoperative
(n  162)
Primary
(n  2290) P value
63.5 69.8 .001
60 (37.0%) 845 (36.9%) .999
10 (6.2%) 112 (4.9%) .453
.001
29 (17.9%) 131 (5.7%)
29 (17.9%) 128 (5.6%)
12 (7.5%) 401 (17.5%) .001
18 (11.3%) 402 (17.6%) .039
18 (14.9%) 253 (14.7%) .895
.319
14 (8.7%) 130 (5.7%)
27 (16.8%) 489 (21.4%)
90 (55.9%) 1350 (59.2%)
30 (18.6%) 312 (13.7%)
.001
40 (24.7%) 950 (41.5%)
0 (0.0%) 25 (1.1%)
16 (9.9%) 297 (13.0%) .583
82 (50.9%) 1333 (58.2%) .083
.001
36 (22.2%) 59 (2.6%)
13 (8.0%) 26 (1.1%)
62 (38.3%) 1350 (59%) .342
20 (32.3%) 487 (36.1%)
5 (3.1%) 130 (9.9%) .483
23 (14.2%) 436 (19.0%) .144
85 (52.5%) 202 (8.8%) .001
49 (30.3%) 1651 (72.1%) .001
8 (5.0%) 120 (5.2%) .999
17 (72.2%) 1674 (73.1%) .316
3 (1.9%) 38 (1.7%)ulat
R
1longer for reoperative than primary procedures. Concomi-
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CDtant CABG was performed more often in the primary group,
whereas the opposite held for interventions on the tricuspid
valve. Although the valve explanted at reoperation was
twice as often biologic as mechanical, mechanical valves
were more often inserted at the time of reoperative AVR.
There were 8 operative deaths (4.9%) in the reoperative
group and 71 operative deaths (3.1%) in the primary group
(Table 3, P  .243). The mortalities among patients under-
going an elective procedure in the absence of bacterial
endocarditis were 4 of 127 (3.2%) in the reoperative group
and 70 of 2231 (3.1%) in the primary group. When patients
who had undergone placement of a stentless xenograft,
homograft, or autograft at the initial or reoperative proce-
dure were excluded from the analysis, the early operative
risks were 4% (5/125 patients) for the reoperative AVR
group and 3.1% (68/2220 patients) for the primary group
(P  .591). When patients who required concomitant pro-
cedures were excluded, postoperative mortalities were 1 of
84 (1.2%) in the reoperative group and 24 of 1090 (2.2%) in
the primary group.
Multivariate analysis of risk factors for early operative
mortality was performed on the combined group of primary
and reoperative AVRs considering age, sex, preoperative
New York Heart Association functional class, preoperative
left ventricular ejection fraction, nonelective surgical status,
reoperative AVR, active endocarditis, prosthetic valve en-
docarditis, preoperative renal failure, previous myocardial
TABLE 2. Operative characteristics of population
Reop
Operative priority (No.)
Elective
Urgent
Emergency
CPB time (min, mean and range)* 103.9
Aortic crossclamp time (min, mean and range)† 67.4 (
Concurrent procedure (No.)
CABG
Tricuspid valve annuloplasty
Tricuspid valve replacement
Intraoperative intra-aortic balloon pump (No.)
Prosthesis explanted (No.)
Mechanical
Xenograft
Homograft
Autograft
Prosthesis inserted (No.)
Mechanical
Xenograft
Homograft
Autograft
*CPB time reported for isolated AVR only.
†Aortic crossclamp time reported for isolated AVR only.infarction, previous CABG, mechanical or bioprosthetic
The Journal of Thoracimplant type, and peripheral vascular disease. Multivariate
predictors for early mortality were prosthetic valve endo-
e (n  162) Primary (n  2290) P value
.175
2.0%) 2173 (94.9%)
.8%) 101 (4.4%)
.2%) 16 (0.7%)
50) n  100 73.8 (20-290) n  1027 .001
0) n  100 51.5 (20-155) n  1027 .001
8.3%) 1263 (55.2%) .001
5.3%) 1113 (48.6%) .001
.7%) 13 (0.6%) .001
.0%) 2 (0.1%) .999
.3%) 47 (2.1%) .001
7.1%) —
7.5%) —
4.2%) —
.2%) —
.001
9.9%) 825 (36.0%)
3.3%) 1415 (61.8%)
.8%) 41 (1.8%)
.0%) 9 (0.4%)
TABLE 3. Operative results for population
Reoperative
(n  162)
Primary
(n  2290)
P
value
Death (No.) 8 (4.9%) 71 (3.1%) .243
Neurologic insult (No.)
Stroke 2 (1.2%) 34 (1.5%) .999
Transient deficit 2 (1.2%) 36 (1.6%) .999
Myocardial infarction (No.) 0 (0.0%) 15 (0.7%) .618
Postoperative intra-aortic
balloon pump (No.)
2 (1.2%) 16 (0.7%) .336
Intubation 48 h (No.) 27 (16.7%) 257 (11.2%) .042
Reexploration for bleeding
(No.)
9 (5.6%) 105 (4.6%) .561
Pneumonia (No.) 5 (3.1%) 51 (2.2%) .415
Pacemaker (No.) 18 (11.1%) 76 (3.3%) .001
Gastrointestinal
complications (No.)
6 (3.7%) 67 (2.9%) .479
Renal failure (No.) 9 (5.6%) 123 (5.4%) .857
Dialysis requirement (No.) 2 (1.2%) 25 (1.1%) .698
Sternal wound infection (No.) 1 (0.6%) 42 (1.8%) .362
Postoperative stay (d, mean
and range)
10.3 (0-71) 9.4 (0-141) .063
Prolonged (14 d) stay (No.) 23 (14.2%) 232 (10.1%) .109
All values represent numbers and percentages of patients in group.erativ
149 (9
11 (6
2 (1
(43-3
26-19
62 (3
41 (2
6 (3
0 (0
15 (9
60 (3
77 (4
23 (1
2 (1
97 (5
54 (3
11 (6
0 (0carditis (P  .001, odds ratio 9.8), advanced preoperative
ic and Cardiovascular Surgery ● Volume 129, Number 1 97
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CDfunctional class (P  .001, odds ratio 2.0), and peripheral
vascular disease (P  .008, odds ratio 2.0). Preserved left
ventricular ejection fraction (P .004, odds ratio 0.98), and
male sex (P  .009, odds ratio 0.49) were protective. After
adjustment for significant predictors identified by the mul-
tivariate model, there was no difference in early mortality
between the groups (P  .095).
Intra-aortic balloon pumps were inserted significantly
more frequently in the reoperative group, and patients un-
dergoing reoperative AVR were more likely to require
prolonged intubation. Postoperative permanent pacemakers
were required three times as often in the reoperative group
as in the primary group. Preoperative predictors of need for
permanent pacemakers included prolonged cardiopulmo-
TABLE 4. Demographic and preoperative clinical characte
M
Age (y, mean)
Female (No.)
Renal insufficiency (No.)
Stroke (No.)
Any
Remote (2 wk)
Peripheral vascular disease (No.)
Diabetes mellitus (No.)
Chronic lung disease (No.)
New York Heart Association functional class (No.)
I
II
III
IV
Angina (No.)
Any
Stable
Myocardial infarction (No.)
Hypertension (No.)
Bacterial endocarditis (No.)
Any
Active
Sinus rhythm (No.)
Preoperative warfarin sodium (No.)
Coronary artery disease
Any disease
Three-vessel disease (No.)
Ejection fraction 30% (No.)
Aortic valve (No.)
Stenosis
Regurgitation
Mixed
Mitral valve (No.)
Stenosis
Regurgitation
Severe regurgitation
Interval from primary AVR (y, median and range)nary bypass (CPB) and aortic crossclamp times, prior AVR,
98 The Journal of Thoracic and Cardiovascular Surgery ● Januapreoperative endocarditis, advanced age, and the degree of
hypothermia during CPB.
Subset Analysis of Reoperative Group
The results obtained among patients undergoing reopera-
tion after previous mechanical or xenograft valve were
then compared. As shown in Table 4, patients undergoing
explantation of aortic xenografts were significantly older
than those having mechanical prostheses replaced, al-
though preoperative stroke was more common among
patients with previous mechanical prostheses. This may
in part reflect the indications for the procedure. Only 2
patients in the previous mechanical group did not have
anticoagulation with warfarin sodium; the first was re-
cs of reoperative group
nical (n  60) Xenograft (n  77) P value
59.5 70.6 .001
6 (43.3%) 22 (28.6%) .104
5 (8.3%) 5 (6.5%) .748
.001
9 (31.7%) 5 (6.5%)
9 (31.7%) 5 (6.5%)
1 (1.7%) 7 (9.1%) .137
7 (11.9%) 10 (13.0%) .999
6 (12.8%) 10 (17.5%) .591
.771
6 (10.0%) 5 (6.5%)
4 (6.7%) 12 (15.6%)
8 (63.3%) 44 (57.1%)
2 (20.0%) 16 (20.8%)
.999
6 (26.7%) 20 (26.0%)
6 (26.7%) 20 (26.0%)
8 (13.3%) 7 (9.2%) .583
7 (45.8%) 47 (61.0%) .085
.067
8 (30.5%) 13 (16.9%)
6 (10.0%) 6 (7.8%)
9 (81.7%) 62 (80.5%) .999
8 (96.7%) 29 (37.7%) 0.001
5 (41.7%) 31 (40.3%) .493
7 (28.0%) 11 (35.5%)
1 (1.7%) 3 (3.9%)
4 (23.3%) 8 (10.4%) .059
2 (53.3%) 38 (49.4%) .731
3 (21.7%) 27 (35.1%) .093
1 (1.7%) 6 (7.9%) .134
4 (57.6%) 65 (85.5%) .001
0 (0.0%) 3 (4.0%)
1 (0-30) 8.6 (0-21) .028risti
echa
2
1
1
3
1
1
1
2
1
4
5
2
1
3
1
3ceiving heparin during a pregnancy and the second was
ry 2005
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CDnoncompliant. Of note, approximately a third of the pa-
tients in the failed xenograft group were receiving war-
farin sodium before reoperation.
Among those with previous xenografts, the indications
for reoperation were structural dysfunction in 59 patients
(76.6%), endocarditis in 7 (9.1%), perivalvular leak in 4
(5.2%), thrombosis or thromboembolism in 3 (3.9%), non-
structural dysfunction from pannus formation in 2 (2.6%),
and progression of coronary artery disease in 2 (2.6%).
Reoperative AVR was indicated among those with previous
mechanical valves for nonstructural dysfunction from pan-
nus formation in 22 (36.7%), perivalvular leak in 19
(31.7%), endocarditis in 11 (18.3%), patient-prosthesis mis-
match in 3 (5.0%), thrombosis or thromboembolism in 3
(5.0%), and structural dysfunction in 2 (3.3%). Both in-
stances of structural dysfunction of mechanical valves were
related to cloth wear of Starr-Edwards valves.
At reoperation, mechanical prostheses were preferentially
implanted in patients with previous mechanical valves. Among
those with previous xenografts, however, biologic and me-
chanical valves were implanted at nearly equal rates (Table 5).
Because of the relatively young age of the reoperative surgical
group, this may have been related to reluctance of the surgeon
to subject the patient to the risk of a third AVR. There was no
difference in early postoperative mortality between those who
underwent reoperation after mechanical and xenograft valves,
as shown in Table 6. Postoperative morbidities were also
similar. There were no deaths among patients undergoing
reoperation for failed homografts or autografts.
Discussion
This study demonstrated similar early operative mortalities
for primary and reoperative AVR at our institution. These
data should encourage an aggressive attitude toward elec-
tive reoperative AVR among patients with acceptable risk
profiles. The observation that advanced functional class and
reduced ejection fraction were predictors of operative risk
reinforces the importance of early referral of patients for
surgery once prosthetic dysfunction has been identified. It
also highlights the importance of serial observation of pa-
tients, whether by the responsible cardiologist or by a car-
diac surgeon, on an ongoing basis after valve replacement.
These results also have implications for the use of bio-
prostheses among younger patients, as is being encouraged
by many in the cardiac surgical community, because these
are the individuals for whom the likelihood of reoperative
AVR is greatest. The data are reassuring that such proce-
dures under elective circumstances carry low risk. This is
particularly true after exclusion of cases of endocarditis, a
complication equally likely to occur with biologic and me-
chanical prostheses.2,3
The operative mortality observed in this study was
slightly less than the 7.8% to 11.5% previously reported.2-12
The Journal of ThoracThis may be due in part to the more contemporary interval
during which these procedures were performed with conse-
quent improvements in myocardial management and post-
operative care. In addition, the potential for selection bias is
significant. The vast majority of patients were operated on
under elective circumstances, and although we would argue
that under appropriate surveillance this should be the case in
all environments, clearly this is not representative of all
practice settings. Still, although our institution is a tertiary
referral center, we also are a significant regional health care
provider, with approximately a third of the patients in this
TABLE 5. Operative characteristics of reoperative group
Mechanical
(n  60)
Xenograft
(n  77) P value
Operative priority (No.) .249
Elective 54 (90.0%) 73 (94.8%)
Urgent 4 (6.7%) 4 (5.2%)
Emergency 2 (3.3%) 0 (0.0%)
Concurrent procedure (No.) 27 (45.0%) 28 (36.4%) .38
CABG 17(28.3%) 20 (26.0%) .999
Tricuspid valve
annuloplasty
4 (6.7%) 2 (2.6%) .404
Intraoperative intra-aortic
balloon pump (No.)
10 (16.7%) 5 (6.5%) .096
Prosthesis inserted (No.) .001
Mechanical 49 (81.7%) 30 (39.0%)
Xenograft 7 (11.7%) 40 (52.0%)
Homograft 4 (6.7%) 7 (9.1%)
TABLE 6. Operative results of reoperative group
Mechanical
(n  60)
Xenograft
(n  77) P value
Death (No.) 4 (6.7%) 4 (5.2%) .73
Neurologic insult (No.)
Stroke 0 (0.0%) 2 (2.6%) .504
Transient deficit 1 (1.7%) 0 (0.0%) .438
Myocardial infarction (No.) 0 (0.0%) 0 (0.0%) .999
Postoperative intra-aortic
balloon pump (No.)
0 (0.0%) 1 (1.3%) .999
Intubation 48 h (No.) 11 (18.3%) 12 (15.6%) .818
Reexploration for bleeding (No.) 3 (5.0%) 4 (5.2%) .999
Pneumonia (No.) 0 (0.0%) 4 (5.2%) .131
Pacemaker (No.) 9 (15.0%) 8 (10.4%) .444
Gastrointestinal complications
(No.)
2 (3.3%) 4 (5.2%) .695
Renal failure (No.) 5 (8.3%) 5 (5.2%) .505
Dialysis requirement (No.) 1 (1.7%) 1 (1.3%) .999
Sternal wound infection (No.) 1 (1.7%) 0 (0.0%) .438
Postoperative stay (d, mean
and range)
9.9 (0-46) 11.4 (0-71) .554
Prolonged (14 d) stay (No.) 7 (11.7%) 13 (16.9%) .469study coming from within 150 miles of our institution.
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CDConsistent with other studies, we found advanced preoper-
ative functional class, prosthetic valve endocarditis, reduced
ejection fraction, female gender, and peripheral vascular dis-
ease to be significant predictors of operative mortality. Previ-
ous studies have also identified advanced age,2,4,7,9,11 gen-
der,4,11,13 weight,7 preoperative renal dysfunction or failure,4,7
nonelective surgical status,4,6 number of previous heart oper-
ations,7 concomitant CABG,7-9,11 double- or triple-vessel by-
pass,11 thrombosis of the prosthesis,14 type and size of bio-
prosthesis,11 tricuspid insufficiency,7 poor hemodynamics,7
repair of ascending aortic aneurysm with a composite graft,7
and concomitant left ventricular aneurysmorrhaphy as signifi-
cant predictors of operative risk. These factors did not achieve
significance in our analysis, perhaps in part because of the
small number of events.
We did not identify previous mechanical prosthesis or
previous bioprosthesis as a risk factor, although other stud-
ies have suggested this to be the case.15,16 Indeed, a previ-
ous study from our institution reported a 10% operative
mortality (1/10 patients) for patients operated on for throm-
bosed aortic disc valves.15 Both of these studies suffered
from small sample size, however, and our current findings
dispute this notion. Our data are insufficient to establish
superiority of either valve type from the standpoint of risk
of complications, because we have only the numerator and
not the denominator of the equation. Without knowledge of
the total number of valves of both types implanted among
the population at risk, rates of endocarditis or pannus for-
mation cannot be calculated. The interval to reoperation was
significantly longer among patients with failed mechanical
aortic valves, which may have contributed to the incidence
of pannus formation as an indication for surgery, although
the mechanisms of pannus formation remain unclear.17 The
difference between groups in endocarditis as an indication
for surgery probably reflects the infrequency of structural
dysfunction as an indication for surgery in the mechanical
group.
Patients undergoing reoperative surgery were more
likely to have an intra-aortic balloon pump inserted than
were those undergoing primary AVR. This may reflect a
cautious approach to these patients among the surgeons
involved, because preoperative ejection fraction and func-
tional class were actually quite similar between groups.
Aortic crossclamp times were somewhat longer in the re-
operative group, although the difference does not appear
clinically significant.
The increased requirement for permanent pacemaker im-
plantation in our reoperative AVR group was similar to
previous reports.18,19 Patients in our reoperative AVR group
more often had endocarditis and had longer CPB and aortic
crossclamp times than the primary group. A previous study
from our institution found that complete atrioventricular
100 The Journal of Thoracic and Cardiovascular Surgery ● Janublock and CPB times longer than 120 minutes predicted
long-term pacemaker dependence.18
Our study suffers from a number of limitations, including
heterogeneity of the study group. Under ideal circum-
stances, a study such as this would include only patients
undergoing isolated AVR. Even in this relatively large
study, however, such inclusion criteria would have resulted
in a sample size of only 84 patients in the reoperative group.
We therefore chose to include only the procedure most
commonly performed with reoperative AVR, CABG, and
procedures that had minimal impact on the operative risk,
namely tricuspid valve interventions. We also combined
patients with failed mechanical and failed bioprosthetic
valves in the reoperative AVR group for comparison with
the primary group. This approach was validated by subset
analysis that demonstrated the operative risk for failed me-
chanical valves was not different from that for failed xeno-
grafts. Despite these measures, the relatively small sample
size limited our power to detect small differences between
the groups and weakens our ability to define risk factors.
Indeed, power analysis of our study demonstrated a 0.18
chance to detect a difference of 0.05 between the primary
and reoperative groups. Additionally, our study is limited by
its retrospective nature and the selection bias inherent in any
surgical series.
Treatment options for patients with aortic valve disease
now include aortic valve repair, the Ross autograft proce-
dure, stentless xenografts, and human homografts, as well as
stented xenografts and mechanical valves. There were in-
sufficient numbers of patients who had undergone these
procedures as primary operations to determine differences
in the risks associated with reoperation; however, the risk
appears low regardless of the type of bioprosthetic valve
used. This is in agreement with previous studies,20 although
all surgeons would argue that reoperative homograft root
replacement after previous homograft root replacement is a
challenging procedure.
Does the risk of reoperative AVR justify the use of tissue
valves in younger patients? Although early operative risk is
only one element of the equation, several large studies
comparing the long-term survival of patients with mechan-
ical versus tissue valves have suggested remarkably similar
survival curves through a 20-year period for patients receiv-
ing tissue and mechanical prostheses.3,12 A higher rate of
death from bleeding complications in the mechanical group
and a higher rate of reoperation in the bioprosthetic group
are expected; thus the risk of the reoperation is a critical
element in determining comparative survival. Patients who
desire an active lifestyle may justifiably choose a tissue
valve, knowingly accepting the risk of reoperative AVR in
the future. Certainly the potential number of reoperations
must be considered for the very young adult, and it must be
recognized that such patients will be older at the time of
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CDtheir reoperation and will probably have more comorbidi-
ties. With close follow-up, however, permitting elective
reoperation before significant left ventricular dysfunction
occurs, our data suggest that that risk associated with this
approach is acceptable.
We thank Ms. Judy R. Lenoch for her assistance with the
computerized database search.
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Discussion
Dr Robert W. Emery (St Paul, Minn). Congratulations to the
Mayo group for this difficult and extensive review. The well-
written article is complex, because they are comparing three
groups: primary AVR and reoperative tissue and mechanical pros-
theses. The points raised are timely, and the recommendations
carry significant implications to patients undergoing AVR. I have
several points and three questions.
First, I am concerned that the time to reoperation in patients
with a biologic prosthesis was short, a mean of 8.6 years. Even
with a low operative risk, this seems an inordinately short time
frame. Even with elective operation, the patients undergoing re-
operation had a higher complexity, as evidenced by the increased
need intra-aortic balloon pumps, prolonged ventilation time, and
longer hospital stay.
Fifty-nine percent of the patients had structural degeneration as
the etiology for valve replacement in the tissue group, versus 3%
for the mechanical group. If this is factored out, then the endocar-
ditis statistics are reversed. It is a risk factor for reoperation and
would have accounted for 44% versus 19% of the reoperation
indications for biologic and mechanical valves, respectively.
The risk of thromboembolism and thrombosis was noted for
mechanical valves, yet the incidences in the series as indications
for reoperation were equal for mechanical and biologic valves.
We were not able to duplicate such excellent results in our
series of reoperative AVRs presented at the American College of
Cardiology in 345 patients followed up for 25 years, with our
mortality being 8%, consistent with the STS database. This study
does not account for patients who might not have been referred
back to this tertiary center, perhaps because of acuity or distance,
which could affect operative mortality and late morbidity.
And finally, with respect the younger patient, our group pre-
sented in the July 2003 Annals of Thoracic Surgery an operative
mortality of 1% and a reoperative incidence of 1.9% among
patients with mechanical valve prostheses, with a total valve-
related event occurrence of 0.3% per patient-year with a 20-year
follow-up of 95.8%. These data need to be taken into account as
you discuss this process with the patient.
For my first question, the incidence of nonstructural dysfunc-
tion from pannus formation was 37% among patients with me-
chanical valves. Could this be accounted for by the significantly
longer time to reoperation in this patient group?
Dr Potter. I think that the mechanism for pannus formation is
quite complex and is yet to be completely defined; however, we do
believe that the time that the mechanical valve is in place is a
significant factor for pannus formation.
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group and 59% of the patients in the mechanical group, as noted in
Table 4, have mitral valve problems yet not have these addressed
at the time of surgery?
Dr Potter. That’s another excellent question. Because of the
retrospective nature of this study, I can’t address it specifically;
however, after reading through all the clinical data and the oper-
ative notes, I can speculate that the consulting surgeon believed
that after AVR the mitral valve disease would improve and that a
double-valve procedure wasn’t in the best interest of the patient.
Dr Emery. Finally, do you know what models of valves
required replacement, particularly mechanical prostheses? Con-
temporary models have a lower incidence of valve-related events
that might lead to replacement than some of the older models that
are no longer used in significant numbers.
Dr Potter. We did not look at each valve individually to
determine the causes of reoperation; however, the 2 incidents of
structural deterioration were both due to Starr-Edwards ball-and-
cage valves that had cloth wear.
Dr John G. Byrne (Boston, Mass). My question relates to the
age cutoff that you would recommend for primary AVR with a
tissue or biologic valve, because obviously if you put a tissue valve
in, say, a 40-year-old, that patient is probably going to see at least
three operations if he or she wants to stay with tissue for a lifetime.
So it is going to be the cumulative lifetime risk of reoperation with
a biologic valve, versus the cumulative lifetime risk of bleeding
with a mechanical valve. So what is the age cutoff that you would
recommend for placing a tissue valve at the primary operation?
Dr Potter. That’s an excellent question. Because I have only
spent time in Dr Sundt’s laboratory and only replaced a few valves
in some pigs, I might have him answer that question for us.
Dr Sundt. Thanks very much for that question. I will note that
Dr Potter is a general surgical resident, and we are very proud of
the job he has done in the laboratory and proud of the job he has
done with this work.
Your question is a great one, and it is difficult to make a firm
recommendation for an individual patient. Ultimately, I think it has
to be the patient who decides on the prosthesis. My job is to advise
about the risks.
Now, the issue about the number of reoperations a 40-year-old
can expect with the tissue option depends on whose statistics you
believe. If you talk to the manufacturers of the current generation
tissue valves, they will tell you their prostheses will last for 20
years or more. If you accept this, that 40-year-old may be facing
only one reoperation in a lifetime.
It is important to recognize that this study cannot answer the
question of mechanical versus tissue completely, because we don’t
have those two comparative groups; we do not have the denomi-
nators, only the numerators, so you can’t really compare them head
to head. It has got to be the patient who decides which set of risks
to face. It is a qualitative issue as much as a quantitative one.
Dr R. Gates (Orange, Calif). It seems as though you have
shown in a well-selected group of patients at a tertiary referral
hospital that you can perform reoperative surgery with a compa-
rable rate of success to that of primary surgery. However, I think
we have to use some caution in extrapolating that into the recom-
mendation to use bioprostheses in younger patients. What you are
102 The Journal of Thoracic and Cardiovascular Surgery ● Janusuggesting is that if you place a tissue valve in a patient at age 65
years is that in 15 years you will be able to replace that valve with
minimal risk.
But the fact is that as patients get older they acquire comor-
bidities, their pulmonary function decreases, they have renal fail-
ure or dysfunction, they have strokes, and many of these patients
are simply not candidates for reoperative surgery regardless of
current bioprosthetic function. Some (many?) of these patients
may be extremely ill, in New York Heart Association class IV, and
in need of reoperation because of a dysfunction bioprostheses.
Now these patients are not in your study because they are too high
risk to be referred back to the Mayo Clinic for surgery. They
simply die with a dysfunctional prosthesis.
So with the great Mayo Clinic database, have you looked at a
cohort of patients who received tissue valves and mechanical
valves in their mid 60s and followed them up until 80 or 85 years
of age? If so, have you seen any difference in survival between the
mechanical and tissue valve groups? In this paired group, I wonder
whether the risk of reoperation was the same as the risk of initial
operation?
Dr Potter. That’s an excellent question. We have not addressed
that question in this study specifically; however, we are in the
process of getting long-term follow-up on our AVR population. I
think what this study can say is that patients with tissue valves who
are followed up closely have routine follow-ups with their cardi-
ologists and echocardiograms and have their aortic valves replaced
when they are dysfunctional, before severe heart failure sets in.
They are going to do much better with their reoperation than are
patients who do not receive follow-up and show up in heart failure
and cardiogenic shock.
Dr Nicholas T. Kouchoukos (St Louis, Mo). If I understand your
data correctly, you excluded patients from this analysis who had more
complex reoperations rather than a simple AVR. Are you comfortable
excluding patients who might have required a root replacement or
resection of an ascending aortic aneurysm as the second procedure
when they had a simple AVR at the first procedure?
Dr Potter. The goal of this study wasn’t to evaluate the
operative mortality for all AVRs. The initial goal was to determine
the risk in younger patients. We did consider looking at the risk in
all patients. I think Dr Sundt may be able to address this a little
better than I, but our goal was more to look at a patient who needed
an AVR when young. Our question was, when that valve slowly
deteriorates, assuming there are no other continued problems, what
is the risk for that patient with deterioration?
Dr Sundt. I take your point, Dr Kouchoukos. At the time of the
first operation, you really don’t know for sure what the second
operation is going to be. In the end, it is just a matter of how you
want to cut the data. In fact, some of my coauthors thought that
even this cut was too inclusive. We tried to make it a pure enough
group to come to some meaningful conclusions looking at just the
risk of the reoperative AVR. Your point is certainly valid, how-
ever. Again, this was not a comparison of initial strategies but
rather a look at just one element of the equation.
Dr Michael P. Siegenthaler (Freiburg, Germany). In most
centers it seems that one or two really experienced surgeons get
referrals for those complex cases such as reoperative AVR. Did
you compare the mortality of those few surgeons who probably did
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words, maybe better surgeons did those complex cases and have a
different practice pattern than the others.
Dr Potter. All the surgeons at the clinic participated and
operated on at least a handful of these patients, and we did not look
at each individual surgeon’s mortality.
Dr Paul Kurlansky (Miami Beach, Fla). This is an excellent
study. I just wanted to comment on the suggestion of one of the
previous questioners that you follow patients from 65 to 75 years
and compare mechanical with tissue valves. We actually did that in
a significant cohort of patients and found, both in terms of oper-
ative mortality and long-term mortality and quality of life, thatThe Journal of ThoraciHowever, if you then broke down the data by propensity scale
analysis, there was absolutely no difference within quintiles be-
tween the groups.
What is the bottom line? The bottom line is that the selection of
patients was different for the mechanical valve than for the tissue
valve. And I think one of the things that you have to take into
account that goes into the surgeon’s choice is not just the age of the
patient but the physiologic age of the patient and the anticipation
of the surgeon of the life expectancy of the patient. The ideal is that
the life expectancy of the valve would be greater than that of the
patient, but if the life expectancy of the patient is not that great,
then regardless of age the choice of a tissue valve would obviouslyA
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